MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in Research Partnership
(Thomson Reuters ONE) - MorphoSys AG / MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in Research Partnership processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today thatShionogi & Co., Ltd., Osaka, Japan, has elected to expand its current researchlicense to cover the use of MorphoSys's HuCAL PLATINUM technology in drugdiscovery. In April 2009, MorphoSys and Shionogi entered into an agreement underwhich, for pre-agreed terms, Shionogi could gain access to HuCAL PLATINUM, thelatest and most powerful MorphoSys antibody library, for a six-month beta testperiod. During this test period, Shionogi was able to compare HuCAL PLATINUMwith its predecessor HuCAL GOLD(®), and found the new library to be considerablybetter."We have had the pleasure of using the MorphoSys HuCAL PLATINUM library for thelast six months and were extremely impressed. HuCAL PLATINUM's capabilities gobeyond any other antibody sourcing library we have used in the past, and we arevery excited about being able to continue to use the PLATINUM library in thefuture," commented Dr. Yoshito Numata, Department Head, Drug Target Discovery,Discovery Research Laboratory."Shionogi has been able to test-drive the latest version of our antibody libraryHuCAL PLATINUM extensively. Thus, their decision to upgrade speaks clearly tothe quality and the success of our internal technology development work inrecent years," commented Dr. Marlies Sproll, Chief Scientific Officer ofMorphoSys.Under the terms of the agreement, Shionogi will now have the right to use HuCALPLATINUM for research purposes at one of its sites. As a result of theexpansion, MorphoSys will receive increased annual user fees from Shionogi.Further financial details were not disclosed.MorphoSys and Shionogi signed a three-year license agreement on the use ofMorphoSys's HuCAL technology in September 2005. Under the terms of theagreement, MorphoSys granted Shionogi access to its HuCAL GOLD antibody libraryfor research applications in Shionogi's drug discovery programs. The researchalliance was extended for three additional years in September 2008. The HuCALPLATINUM library was introduced in September 2008. PLATINUM contains severalsignificant improvements over the previous version of the HuCAL library. The newlibrary is based on the genetic information of approximately 45 billiondifferent fully human antibodies.About MorphoSys:MorphoSys is an independent biotechnology company that develops novel antibodiesfor therapeutic, diagnostic and research applications. The Company's HuCALtechnology is one of the most powerful methods available for generating fullyhuman antibodies. By successfully applying this and other proprietarytechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human health-care.Through its alliances with some of the world's leading pharmaceutical companies,MorphoSys has created a pipeline of more than 60 drug candidates. The Company isexpanding its drug pipeline by adding new partnered programs, and by building aportfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,the Company is focused on the areas of oncology and inflammation. Its mostadvanced program MOR103, a first-in-class, fully human antibody against GM-CSF,is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.Via its business unit AbD Serotec, MorphoSys is expanding the reach of itstechnologies in the diagnostics and research markets. MorphoSys is headquarteredin Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol"MOR". For further information, visit http://www.morphosys.com/HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(® )and RapMAT(®) areregistered trademarks of MorphoSys AG.This communication contains certain forward-looking statements concerning theMorphoSys group of companies. The forward-looking statements contained hereinrepresent the judgment of MorphoSys as of the date of this release and involverisks and uncertainties. Should actual conditions differ from the Company'sassumptions, actual results and actions may differ from those anticipated.MorphoSys does not intend to update any of these forward-looking statements asfar as the wording of the relevant press release is concerned.For more information, please contact MorphoSys:Dr. Claudia Gutjahr-L?Head of Corporate Communications & IRTel: +49 (0) 89 / 899 27-122Mario BrkuljSenior Manager Corporate Communications & IRTel: +49 (0) 89 / 899 27-454Jessica KulpiSpecialist Corporate Communications & IRTel: +49 (0) 89 / 899 27-332investors(at)morphosys.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.01.2010 - 01:30 Uhr
Sprache: Deutsch
News-ID 1009530
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 132 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in Research Partnership
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
